Retatrutide is not approved, has no official price, and cannot be safely bought online. Lilly plans to file with the FDA in the first quarter of 2027, and a decision would likely come in late 2027 or 2028. Until then, clinical trials and approved medicines are the legitimate options. What is the availability summary? Retatrutide is an investigational once weekly triple agonist acting on GIP,...